Abstract
Iron chelation therapy is used to remove iron in cases of iron poisoning and Cooley’s Anemia. Cooley’s Anemia is characterized by an inability to synthesize the 3-chain of hemoglobin. Frequent transfusion, the primary treatment, introduces iron, which if not removed, accumulates to toxic levels. Deferioxamine-B(DFB), a naturally occurring tris-hydroxamic acid, is presently used to treat this condition. The structural positions of the three hydroxamic acids of DFB provides a powerful chelate effect and enhances iron binding. Modeled after DFB, vinyl polymers were constructed for potential use in iron chelation. The polymer and spacers position the hydroxamic acids in a way that provides good chelation effects. Bioassay in a mouse screen (Mason Research Institute) shows that many of the polymers are active in removing iron in vivo. We will discuss the effect of subtle changes in the structure of the polymer on the bioactivity and the tox-icity. Such changes include the nature of the spacer group and the presence or absence of a methyl group on a polymer chain or nitrogen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
H. S. Waxman and E. B. Brown, in: “Progress in Hematology”, Vol. VI, E. B. Brown and C. V. Moore, eds., Grune and Stratton, 1969, p 338.
A. I. Chernoff, Blood, The Journal of Hematology, 14, 899 (1959).
T. F. Necheles, D. M. Allen, and H. E. Finkel, “Clinical Disorders of Hemoglobin Structure and Synthesis”, Meredith Corp., New York, 1969.
D. J. Weatherall, in: “Development of Iron Chelators for Clinical Use”, A. E. Martell, W. F. Anderson, and D. G. Badman, eds., Elsevier North Holland, Inc., New York 1981, p. 3.
Assessment of Cooley’s Anemia Reaserch and Treatment, DHEW Publication No. (NIH) 79-1653, March 1979.
B. Modell in: “Progress in Hematology”, Vol. XI, E. B. Brown, ed., Grune and Stratton, New York, 1979, p 267.
W. F. Anderson in: “Inorganic Chemistry in Biology and Medicine”, A. E. Martell, ed., ACS Symposium Series 140, American Chemical Society, Washington, DC, 1980, p 251.
E. C. Zaino and R. H. Roberts, eds., “Chelation Therapy in Chronic Iron Overload”, Symposia Specialists, Inc., Miami, Florida, 1977.
W. F. Anderson and M. C. Hiller, eds., “Development of Iron Chelators for Clinical Use”, U. S. Dept. of Health Education and Welfare, DHEW Publication No. (NIH) 77-994, Bethesda, MD, 1975.
D. J. Weatherall and J. B. Clegg, “The Thalassaemia Syndromes”, 3rd ed., Blackwell Scientific Publications, Oxford, 1981.
R. D. Proper and D. G. Nathan in: “Chelation Therapy in Chronic Iron Overload”, E. C. Zaino and R. H. Roberts, eds., Symposia Specialists, Miami, Florida, 1977, p 17.
A. Winston and D. Kirchner, Macromolecules, 11, 597, (1978).
D. V. P. R. Varaprasad, J. Rosthauser, and A. Winston, J. Polym. Sci., Chem. Ed., 22, 2131, (1984).
A. Winston, D. V. P. R. Varaprasad, J. J. Metterville, and H. Rosenkrantz, J. Pharmacol. Exp. Ther., 232, 644 (1985).
C. G. Pitt, G. Gupta, W. E. Estes, H. Rosenkrantz, J. J. Metterville, A. L. Crumbliss, R. A. Palmer, K. W. Nordquest, K. A. Sprinkle Hardy, D. R. Whitcomb, B. R. Byers, J. E. L. Arceneaux, C. G. Gaines, C. V. Sciortino, J. Pharmacol. Exp. Ther., 208, 12 (1979).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer Science+Business Media New York
About this chapter
Cite this chapter
Winston, A., Varaprasad, D.V.P.R., Metterville, J.J., Rosenkrantz, H. (1985). Polymeric Hydroxamic Acids for Iron Chelators Therapy. In: Gebelein, C.G., Carraher, C.E. (eds) Polymeric Materials in Medication. Polymer Science and Technology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2245-8_17
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2245-8_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-2247-2
Online ISBN: 978-1-4899-2245-8
eBook Packages: Springer Book Archive